Quick read
Researchers are testing angiotensin II to treat vasoplegia in cardiac surgery patients, a potentially life-threatening condition.
What's happening
A clinical trial is underway to investigate the use of angiotensin II, a peptide hormone, to treat vasoplegia in patients after cardiac surgery. The trial is listed on ClinicalTrials.gov and is currently recruiting participants.
Why this matters to you
ā¢This peptide has already been FDA-approved for other uses, which could speed up its approval for this new application.
ā¢Vasoplegia is a serious condition that can occur after cardiac surgery, and current treatments are often ineffective.
ā¢If successful, this treatment could save lives and improve outcomes for patients after heart surgery.
Let's talk about it
Do you think the use of angiotensin II for vasoplegia treatment could lead to a paradigm shift in post-cardiac surgery care?